{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:59:21Z","timestamp":1788919161113,"version":"build-2803163510"},"reference-count":152,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":550,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1124\/jpet.122.001563","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T18:00:14Z","timestamp":1683223214000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease"],"prefix":"10.1016","volume":"386","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-5258","authenticated-orcid":false,"given":"Anbukkarasi","family":"Muniyandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella D.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Mijit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-1826","authenticated-orcid":false,"given":"Mark R.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-7875","authenticated-orcid":false,"given":"Timothy W.","family":"Corson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001563_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ICU.0000000000000851","article-title":"Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration","volume":"33","author":"Adamis","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","article-title":"Current understanding of the molecular and cellular pathology of diabetic retinopathy","volume":"17","author":"Antonetti","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/jpet.122.001563_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1124\/jpet.122.001563_bib4","article-title":"Encapsulated RUNX1 inhibitor (Ro24-7429) reduces angiogenesis in retinal endothelial cells","volume":"63","author":"Arevalo-Alquichire","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/175163","article-title":"ROCK as a therapeutic target of diabetic retinopathy","volume":"2010","author":"Arita","year":"2010","journal-title":"J Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1734-1140(10)70311-X","article-title":"Cytochrome P450-dependent metabolism of \u03c9-6 and \u03c9-3 long-chain polyunsaturated fatty acids","volume":"62","author":"Arnold","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1124\/jpet.122.001563_bib7","doi-asserted-by":"crossref","first-page":"32720","DOI":"10.1074\/jbc.M110.118406","article-title":"Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of \u03c9-3 fatty acids","volume":"285","author":"Arnold","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.122.001563_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.118.248427","article-title":"Ocular distribution and pharmacodynamics of SF0166, a topically administered \u03b1v\u03b23 integrin antagonist, for the treatment of retinal diseases","volume":"366","author":"Askew","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001563_bib9","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.3390\/molecules25153468","article-title":"Pharmacological potential of small molecules for treating corneal neovascularization","volume":"25","author":"Barry","year":"2020","journal-title":"Molecules"},{"key":"10.1124\/jpet.122.001563_bib10","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1021\/acs.jmedchem.5b00449","article-title":"Synthesis and biological evaluation of novel homoisoflavonoids for retinal neovascularization","volume":"58","author":"Basavarajappa","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001563_bib11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.15252\/emmm.201606561","article-title":"Ferrochelatase is a therapeutic target for ocular neovascularization","volume":"9","author":"Basavarajappa","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1124\/jpet.122.001563_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13643-020-01562-9","article-title":"Effectiveness of interventions to increase uptake and completion of treatment for diabetic retinopathy in low- and middle-income countries: a rapid review protocol","volume":"10","author":"Bascaran","year":"2021","journal-title":"Syst Rev"},{"key":"10.1124\/jpet.122.001563_bib13","article-title":"The safety of APX3330, an oral drug candidate for the treatment of diabetic eye disease, in the ongoing masked 24-week ZETA-1 Phase 2 clinical trial","volume":"63","author":"Boyer","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20220923-02","article-title":"The safety and biological activity of OTT166, a novel topical selective integrin inhibitor for the treatment of diabetic eye disease: a Phase 1b study","volume":"53","author":"Boyer","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1124\/jpet.122.001563_bib15","first-page":"91","article-title":"Dietary deficiency of N-3 fatty acids alters rhodopsin content and function in the rat retina","volume":"35","author":"Bush","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib16","doi-asserted-by":"crossref","first-page":"39211","DOI":"10.1038\/srep39211","article-title":"Epoxygenated fatty acids inhibit retinal vascular inflammation","volume":"6","author":"Capozzi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib17","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1167\/iovs.14-14216","article-title":"The role of cytochrome P450 epoxygenases in retinal angiogenesis","volume":"55","author":"Capozzi","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047462","article-title":"APE1\/Ref-1 regulates STAT3 transcriptional activity and APE1\/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival","volume":"7","author":"Cardoso","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.122.001563_bib19","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.4049\/jimmunol.0901511","article-title":"The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis","volume":"183","author":"Carmi","year":"2009","journal-title":"J Immunol"},{"key":"10.1124\/jpet.122.001563_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.drudis.2020.10.015","article-title":"The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease","volume":"26","author":"Caston","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.122.001563_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0003-9861(83)90628-8","article-title":"The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase","volume":"223","author":"Chacos","year":"1983","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/jpet.122.001563_bib22","article-title":"Sustained delivery of griseofulvin by polymeric microparticles for neovascular eye disease treatment","volume":"62","author":"Chobisa","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4068\/cmj.2016.52.2.75","article-title":"Dynamic regulation of APE1\/Ref-1 as a therapeutic target protein","volume":"52","author":"Choi","year":"2016","journal-title":"Chonnam Med J"},{"key":"10.1124\/jpet.122.001563_bib24","series-title":"Retinal Degenerative Diseases","first-page":"9","article-title":"A review of pathogenic drivers of age-related macular degeneration, beyond complement, with a focus on potential endpoints for testing therapeutic interventions in preclinical studies","author":"Choudhary","year":"2019"},{"key":"10.1124\/jpet.122.001563_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.preteyeres.2015.09.004","article-title":"Connexin43 in retinal injury and disease","volume":"51","author":"Danesh-Meyer","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1124\/jpet.122.001563_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib28","doi-asserted-by":"crossref","first-page":"20554","DOI":"10.1038\/s41598-020-77254-0","article-title":"Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy","volume":"10","author":"Delgado-Tirado","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib29","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib30","first-page":"510","article-title":"Immunohistochemical study of STAT3, HIF-1\u03b1 and VEGF in pterygium and normal conjunctiva: Experimental research and literature review","volume":"26","author":"Dong","year":"2020","journal-title":"Mol Vis"},{"key":"10.1124\/jpet.122.001563_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib32","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1124\/jpet.122.001563_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2017.09.039","article-title":"DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA repair function of APE1","volume":"366","author":"Fehrenbacher","year":"2017","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.122.001563_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.abb.2008.01.002","article-title":"Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450","volume":"471","author":"Fer","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/jpet.122.001563_bib35","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3390\/ijms23052592","article-title":"Exudative versus nonexudative age-related macular degeneration: physiopathology and treatment options","volume":"23","author":"Fernandes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib36","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.survophthal.2022.11.007","article-title":"Retinopathy of prematurity: A review of pathophysiology and signaling pathways","volume":"68","author":"Fevereiro-Martins","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib38","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1535-7163.MCT-11-0107","article-title":"Impact of APE1\/Ref-1 redox inhibition on pancreatic tumor growth","volume":"10","author":"Fishel","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.122.001563_bib39","doi-asserted-by":"crossref","unstructured":"Fishel ML, Cheng H, Shahda S, Kelley MR (2015) APX3330 drug development for clinical trials targeting APE1\/Ref-1 in pancreatic cancer, in AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Mol Cancer Ther December 2015; B167, Boston, MA","DOI":"10.1158\/1535-7163.TARG-15-B167"},{"key":"10.1124\/jpet.122.001563_bib40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.exphem.2010.08.011","article-title":"Inhibition of the redox function of APE1\/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis","volume":"38","author":"Fishel","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1124\/jpet.122.001563_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/jpet.122.001563_bib42","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMct1000495","article-title":"Ranibizumab therapy for neovascular age-related macular degeneration [published correction appears in N Engl J Med (2010) 363:2474]","volume":"363","author":"Folk","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001563_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6654168","article-title":"Intravitreal therapy for diabetic macular edema: an update","volume":"2021","author":"Furino","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3945\/ajcn.117.153825","article-title":"\u03c9-3 and \u03c9-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases","volume":"106","author":"Gong","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/jpet.122.001563_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajpath.2020.12.005","article-title":"Treatment of experimental choroidal neovascularization via RUNX1 inhibition","volume":"191","author":"Gonzalez-Buendia","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.122.001563_bib46","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001563_bib47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-030-21162-2_8","article-title":"Inflammatory ocular diseases and sphingolipid signaling","volume":"1159","author":"Grambergs","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/jpet.122.001563_bib48","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1124\/jpet.122.001563_bib49","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.bbamcr.2012.04.009","article-title":"One ring to rule them all: trafficking of heme and heme synthesis intermediates in the metazoans","volume":"1823","author":"Hamza","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.122.001563_bib50","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001563_bib51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-014-1419-0","article-title":"Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro","volume":"118","author":"Han","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1124\/jpet.122.001563_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","article-title":"Soluble epoxide hydrolase: gene structure, expression and deletion","volume":"526","author":"Harris","year":"2013","journal-title":"Gene"},{"key":"10.1124\/jpet.122.001563_bib53","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.3390\/ijms221910279","article-title":"Inhibition of APE1\/Ref-1 for neovascular eye diseases: from biology to therapy","volume":"22","author":"Hartman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib54","doi-asserted-by":"crossref","first-page":"E7545","DOI":"10.1073\/pnas.1620898114","article-title":"Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization","volume":"114","author":"Hasegawa","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERandomizedandomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001563_bib56","first-page":"133","article-title":"APE1\/Ref-1 as a novel target for retinal diseases","volume":"2","author":"Heisel","year":"2021","journal-title":"J Cell Signal"},{"key":"10.1124\/jpet.122.001563_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000463238","article-title":"Suppression of retinal neovascularization by anti-ccr3 treatment in an oxygen-induced retinopathy model in mice","volume":"58","author":"Hirahara","year":"2017","journal-title":"Ophthalmic Res"},{"key":"10.1124\/jpet.122.001563_bib58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4049\/jimmunol.160.2.810","article-title":"Nuclear targeted suppression of NF-\u03ba B activity by the novel quinone derivative E3330","volume":"160","author":"Hiramoto","year":"1998","journal-title":"J Immunol"},{"key":"10.1124\/jpet.122.001563_bib59","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3345\/cep.2021.00773","article-title":"Retinopathy of prematurity: a review of epidemiology and current treatment strategies","volume":"65","author":"Hong","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"10.1124\/jpet.122.001563_bib61","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.ophtha.2020.03.034","article-title":"Poorer outcomes in real-world studies of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"127","author":"Hsu","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature25013","article-title":"Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy","volume":"552","author":"Hu","year":"2017","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001563_bib63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1084\/jem.20131494","article-title":"M\u00fcller glia cells regulate Notch signaling and retinal angiogenesis via the generation of 19,20-dihydroxydocosapentaenoic acid","volume":"211","author":"Hu","year":"2014","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.122.001563_bib64","series-title":"IDF Diabetes Atlas","year":"2021"},{"key":"10.1124\/jpet.122.001563_bib65","doi-asserted-by":"crossref","first-page":"18996","DOI":"10.1038\/s41598-021-98568-7","article-title":"Patient preferences in retinal drug delivery","volume":"11","author":"Jacobs","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib66","first-page":"379","article-title":"Apurinic\/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages","volume":"31","author":"Jedinak","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.122.001563_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.visres.2010.10.008","article-title":"Inhibition of APE1\/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo","volume":"51","author":"Jiang","year":"2011","journal-title":"Vision Res"},{"key":"10.1124\/jpet.122.001563_bib68","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/cam4.1360","article-title":"PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1124\/jpet.122.001563_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1874467211205010036","article-title":"APE1\/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair\/redox protein APE1\/Ref-1","volume":"5","author":"Kelley","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/jpet.122.001563_bib70","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1089\/ars.2010.3410","article-title":"Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease\/redox signaling enzyme APE1\/Ref-1","volume":"14","author":"Kelley","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.122.001563_bib71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.actbio.2019.07.054","article-title":"Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization","volume":"97","author":"Kim","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1124\/jpet.122.001563_bib72","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bbrc.2007.08.100","article-title":"Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression","volume":"362","author":"Kim","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001563_bib73","first-page":"556","article-title":"Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor","volume":"14","author":"Kim","year":"2008","journal-title":"Mol Vis"},{"key":"10.1124\/jpet.122.001563_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/aes-21-4","article-title":"Inflammatory pathways in pathological neovascularization in retina and choroid: a narrative review on the inflammatory drug target molecules in retinal and choroidal neovascularization","volume":"6","author":"Kim","year":"2021","journal-title":"Ann Eye Sci"},{"key":"10.1124\/jpet.122.001563_bib75","article-title":"Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR\/DME clinical dose with sufficient distribution to human retina using PBPK modeling","volume":"62","author":"Lachi Silva","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib76","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.2337\/db16-1035","article-title":"Identification of RUNX1 as a mediator of aberrant retinal angiogenesis","volume":"66","author":"Lam","year":"2017","journal-title":"Diabetes"},{"key":"10.1124\/jpet.122.001563_bib77","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1039\/C4OB01604A","article-title":"The first synthesis of the antiangiogenic homoisoflavanone, cremastranone","volume":"12","author":"Lee","year":"2014","journal-title":"Org Biomol Chem"},{"key":"10.1124\/jpet.122.001563_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/ars.2013.5492","article-title":"Human apurinic\/apyrimidinic endonuclease 1","volume":"20","author":"Li","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.122.001563_bib79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.redox.2014.01.023","article-title":"Inhibition of APE1\/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization","volume":"2","author":"Li","year":"2014","journal-title":"Redox Biol"},{"key":"10.1124\/jpet.122.001563_bib80","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1167\/iovs.14-14451","article-title":"Suppression of choroidal neovascularization through inhibition of APE1\/Ref-1 redox activity","volume":"55","author":"Li","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib81","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1177\/0963689719885083","article-title":"PRMT5 promotes human lung cancer cell apoptosis via Akt\/Gsk3\u03b2 signaling induced by resveratrol","volume":"28","author":"Li","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1124\/jpet.122.001563_bib82","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1089\/ars.2008.2120","article-title":"Role of the multifunctional DNA repair and redox signaling protein Ape1\/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1","volume":"10","author":"Luo","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/jpet.122.001563_bib83","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/ijms22010298","article-title":"Tonabersat inhibits connexin43 hemichannel opening and inflammasome activation in an in vitro retinal epithelial cell model of diabetic retinopathy","volume":"22","author":"Lyon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib84","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/17460441.2018.1430136","article-title":"Models of retinal diseases and their applicability in drug discovery","volume":"13","author":"Malek","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/jpet.122.001563_bib85","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13311-019-00786-5","article-title":"Connexin hemichannel block using orally delivered tonabersat improves outcomes in animal models of retinal disease","volume":"17","author":"Mat Nor","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.122.001563_bib86","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","article-title":"Outcomes of over 40,000 eyes treated for diabetic macula edema in routine clinical practice: a systematic review and meta-analysis","volume":"39","author":"Mehta","year":"2022","journal-title":"Adv Ther"},{"key":"10.1124\/jpet.122.001563_bib87","first-page":"151","article-title":"APE1\/Ref-1 - one target with multiple indications: emerging aspects and new directions","volume":"2","author":"Mijit","year":"2021","journal-title":"J Cell Signal"},{"key":"10.1124\/jpet.122.001563_bib88","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/ijms24021101","article-title":"Identification of novel pathways regulated by APE1\/Ref-1 in human retinal endothelial cells","volume":"24","author":"Mijit","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib89","doi-asserted-by":"crossref","first-page":"10431","DOI":"10.1073\/pnas.88.23.10431","article-title":"t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1","volume":"88","author":"Miyoshi","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib90","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41598-023-28215-w","article-title":"PRMT5 is a therapeutic target in choroidal neovascularization","volume":"13","author":"Muniyandi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib91","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1073\/pnas.0408835103","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.122.001563_bib93","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.RES.83.9.932","article-title":"Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation","volume":"83","author":"Oltman","year":"1998","journal-title":"Circ Res"},{"key":"10.1124\/jpet.122.001563_bib94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2019.00095","article-title":"Soluble epoxide hydrolase inhibition for ocular diseases: vision for the future","volume":"10","author":"Park","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.122.001563_bib95","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.3390\/ijms232415595","article-title":"Decreased expression of soluble epoxide hydrolase suppresses murine choroidal neovascularization","volume":"23","author":"Park","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib96","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib97","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41418-017-0001-7","article-title":"Heme accumulation in endothelial cells impairs angiogenesis by triggering paraptosis","volume":"25","author":"Petrillo","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1124\/jpet.122.001563_bib98","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1039\/C7MB00391A","article-title":"Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases","volume":"13","author":"Prabhu","year":"2017","journal-title":"Mol Biosyst"},{"key":"10.1124\/jpet.122.001563_bib99","doi-asserted-by":"crossref","first-page":"12419","DOI":"10.1096\/fj.202000964R","article-title":"Ferrochelatase regulates retinal neovascularization","volume":"34","author":"Pran Babu","year":"2020","journal-title":"FASEB J"},{"key":"10.1124\/jpet.122.001563_bib100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12964-019-0344-4","article-title":"PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7\/cMyc axis","volume":"17","author":"Qin","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1124\/jpet.122.001563_bib101","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/748361","article-title":"Retina and omega-3","volume":"2011","author":"Querques","year":"2011","journal-title":"J Nutr Metab"},{"key":"10.1124\/jpet.122.001563_bib102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1124\/jpet.122.001563_bib103","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.3390\/ijms21218242","article-title":"Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches","volume":"21","author":"Ricci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib104","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/ijms19040942","article-title":"Role of inflammation in diabetic retinopathy","volume":"19","author":"R\u00fcbsam","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.122.001563_bib105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ibd\/izaa161","article-title":"Inhibition of APE1\/Ref-1 redox signaling alleviates intestinal dysfunction and damage to myenteric neurons in a mouse model of spontaneous chronic colitis","volume":"27","author":"Sahakian","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1124\/jpet.122.001563_bib106","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1124\/jpet.118.248088","article-title":"Ref-1\/APE1 inhibition with novel small molecules blocks ocular neovascularization","volume":"367","author":"Sardar Pasha","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001563_bib107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-017-0023-0","article-title":"Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic","volume":"1","author":"Shah","year":"2017","journal-title":"NPJ Precis Oncol"},{"key":"10.1124\/jpet.122.001563_bib108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/ATVBAHA.113.302927","article-title":"Cytochrome P450 2C8 \u03c93-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization--brief report","volume":"34","author":"Shao","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/jpet.122.001563_bib109","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1089\/dna.2012.1786","article-title":"New biomarker for neovascular age-related macular degeneration: eotaxin-2","volume":"31","author":"Sharma","year":"2012","journal-title":"DNA Cell Biol"},{"key":"10.1124\/jpet.122.001563_bib110","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3389\/fphar.2020.01015","article-title":"Mitochondrial heme synthesis enzymes as therapeutic targets in vascular diseases","volume":"11","author":"Shetty","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.122.001563_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101391","article-title":"Heme synthesis inhibition blocks angiogenesis via mitochondrial dysfunction","volume":"23","author":"Shetty","year":"2020","journal-title":"iScience"},{"key":"10.1124\/jpet.122.001563_bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2004-815496","article-title":"Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata","volume":"70","author":"Shim","year":"2004","journal-title":"Planta Med"},{"key":"10.1124\/jpet.122.001563_bib113","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.chembiol.2022.01.001","article-title":"Small-molecule inhibitors of ferrochelatase are antiangiogenic agents","volume":"29","author":"Sishtla","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1124\/jpet.122.001563_bib114","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.122.001563_bib115","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/prot.22747","article-title":"Hemeproteins--diversity in structural characteristics, function, and folding","volume":"78","author":"Smith","year":"2010","journal-title":"Proteins"},{"key":"10.1124\/jpet.122.001563_bib116","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","article-title":"The expanding role of vascular endothelial growth factor inhibitors in ophthalmology","volume":"87","author":"Stewart","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/jpet.122.001563_bib117","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/IAE.0000000000003446","article-title":"Safety and therapeutic effects of orally administered AKST4290 in newly diagnosed neovascular age-related macular degeneration","volume":"42","author":"Stewart","year":"2022","journal-title":"Retina"},{"key":"10.1124\/jpet.122.001563_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-3084(03)00101-4","article-title":"Docosahexaenoic acid: membrane properties of a unique fatty acid","volume":"126","author":"Stillwell","year":"2003","journal-title":"Chem Phys Lipids"},{"key":"10.1124\/jpet.122.001563_bib119","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0022-2275(20)41904-2","article-title":"Recycling of docosahexaenoic acid in rat retinas during n-3 fatty acid deficiency","volume":"32","author":"Stinson","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1124\/jpet.122.001563_bib120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/bi101248s","article-title":"Interactions of apurinic\/apyrimidinic endonuclease with a redox inhibitor: evidence for an alternate conformation of the enzyme","volume":"50","author":"Su","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.122.001563_bib121","doi-asserted-by":"crossref","first-page":"25509","DOI":"10.1038\/srep25509","article-title":"A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy","volume":"6","author":"Sulaiman","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib122","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/acschembio.7b00854","article-title":"Chemical proteomics reveals soluble epoxide hydrolase as a therapeutic target for ocular neovascularization","volume":"13","author":"Sulaiman","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.122.001563_bib123","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","article-title":"Complement factor H in AMD: Bridging genetic associations and pathobiology","volume":"62","author":"Toomey","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1124\/jpet.122.001563_bib124","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicenter randomized double masked study","volume":"340","author":"Tufail","year":"2010","journal-title":"BMJ"},{"key":"10.1124\/jpet.122.001563_bib125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pharmaceutics13020288","article-title":"Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases","volume":"13","author":"Wan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/jpet.122.001563_bib126","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/780634","article-title":"Drug delivery implants in the treatment of vitreous inflammation","volume":"2013","author":"Wang","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1124\/jpet.122.001563_bib127","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1038\/s41598-017-10124-4","article-title":"TGF-\u03b2 participates choroid neovascularization through Smad2\/3-VEGF\/TNF-\u03b1 signaling in mice with laser-induced wet age-related macular degeneration","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001563_bib128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4161\/cc.27353","article-title":"Protein arginine methylation of non-histone proteins and its role in diseases","volume":"13","author":"Wei","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.122.001563_bib129","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1073\/pnas.1311784110","article-title":"PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib130","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","article-title":"Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice","volume":"38","author":"Weiss","year":"2018","journal-title":"Retina"},{"key":"10.1124\/jpet.122.001563_bib131","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001668R","article-title":"TNF-\u03b1 signaling regulates RUNX1 function in endothelial cells","volume":"35","author":"Whitmore","year":"2021","journal-title":"FASEB J"},{"key":"10.1124\/jpet.122.001563_bib132","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1124\/jpet.122.001563_bib133","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9402198","article-title":"Association between aqueous cytokines and diabetic retinopathy stage","volume":"2017","author":"Wu","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1124\/jpet.122.001563_bib134","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1124\/jpet.122.001563_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001898","article-title":"RUNX1 can mediate the glucose and O-GlcNAc-driven proliferation and migration of human retinal microvascular endothelial cells","volume":"9","author":"Xing","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1124\/jpet.122.001563_bib136","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","article-title":"Para-inflammation in the aging retina","volume":"28","author":"Xu","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1124\/jpet.122.001563_bib137","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.18632\/aging.202407","article-title":"PRMT5 regulates colorectal cancer cell growth and EMT via EGFR\/Akt\/GSK3\u03b2 signaling cascades","volume":"13","author":"Yan","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1124\/jpet.122.001563_bib138","first-page":"83","article-title":"Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation","volume":"24","author":"Yan","year":"2018","journal-title":"Mol Vis"},{"key":"10.1124\/jpet.122.001563_bib139","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1073\/pnas.1401191111","article-title":"Cytochrome P450-generated metabolites derived from \u03c9-3 fatty acids attenuate neovascularization","volume":"111","author":"Yanai","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib140","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.122.001563_bib141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.122.001563_bib142","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/jpet.303.2.768","article-title":"Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels","volume":"303","author":"Ye","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001563_bib143","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/vision2030031","article-title":"New therapies of neovascular AMD-beyond anti-VEGFs","volume":"2","author":"Yerramothu","year":"2018","journal-title":"Vision (Basel)"},{"key":"10.1124\/jpet.122.001563_bib144","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.plipres.2013.11.003","article-title":"Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer","volume":"53","author":"Zhang","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1124\/jpet.122.001563_bib145","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1073\/pnas.1304321110","article-title":"Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.122.001563_bib146","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1021\/bi400179m","article-title":"Inhibition of apurinic\/apyrimidinic endonuclease I\u2019s redox activity revisited","volume":"52","author":"Zhang","year":"2013","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.122.001563_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.108969","article-title":"Runx1 regulates Tff1 expression to expedite viability of retinal microvascular endothelial cells in mice with diabetic retinopathy","volume":"217","author":"Zhang","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.122.001563_bib148","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbrc.2018.11.036","article-title":"The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma","volume":"507","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.122.001563_bib149","doi-asserted-by":"crossref","first-page":"H2430","DOI":"10.1152\/ajpheart.2001.280.6.H2430","article-title":"EET homologs potently dilate coronary microvessels and activate BK(Ca) channels","volume":"280","author":"Zhang","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/jpet.122.001563_bib150","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41419-019-2108-x","article-title":"RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGF\u03b2 pathway-dependent manner","volume":"10","author":"Zhao","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1124\/jpet.122.001563_bib151","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.11.6.17","article-title":"Sema3A Antibody BI-X prevents cell permeability and cytoskeletal collapse in HRMECs and increases tip cell density in mouse oxygen-induced retinopathy","volume":"11","author":"Zippel","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"10.1124\/jpet.122.001563_bib152","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193256","article-title":"p38 promoted retinal micro-angiogenesis through up-regulated RUNX1 expression in diabetic retinopathy","volume":"40","author":"Zou","year":"2020","journal-title":"Biosci Rep"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T11:51:24Z","timestamp":1740657084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0022356524170425"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001563","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}